INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)	ATTY. DOCKET NO. 066783-0145	SERIAL NO. 10/782,375
	APPLICANT Pulst et al.	
	FILING DATE February 18, 2004	GROUP 1645

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS	CITE NO.	Document Number Number-Kind Code2 (if known)		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1.	US	2002/0155577	10-24-2002		

FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS	CITE NO.	Foreign Patent Document Country Codes3-Number 4-Kind Codes (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Figures Appear	Translation Yes	Translation No
	2.	WO 02/24721	03-28-2002				

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER'S INITIALS	CITE NO.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
	3.	ABBAS et al.," A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe. French Parkinson's Disease Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinson's Disease," Hum. Mol. Genet. 8:567-574 (1999).	
	4.	BEITES et al., "The septin CDCrel-1 binds syntaxin and inhibits exocytosis," Nat. Neurosci. 2(5):434-439 (1999).	
	5.	BERTON et al., "Synaptotagmin I and IV define distinct populations of neuronal transport vesicles," Eur. J. Neurosci. 12:1294-1302 (2000).	
	6.	BOMMERT et al., "Inhibition of neurotransmitter release by C2-domain peptides implicates synaptotagmin in exocytosis," Nature 363:163-165 (1993).	
	7.	BONIFATI et al., "Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism," Science 299:256-259 (2003).	
	8.	CHUNG et al., "Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease," Nat. Med. 7:1144-1150 (2001).	
	9.	CORTI et al., "The p38 subunit of the aminoacyl-tRNA synthetase complex is a Parkin substrate: linking protein biosynthesis and neurodegeneration," Hum Mol. Genet. 12:1427-1437 (2003).	
	10.	DAMIER et al., "The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease," Brain 122:1437-1448 (1999).	
	11.	DAVIS et al., "Kinetics of synaptotagmin responses to Ca2+ and assembly with the core SNARE complex onto membranes," Neuron. 24:363-376 (1999).	

EXAMINER	DATE CONSIDERED
/Stephen Gucker/	06/21/2010

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
** This reference not attached. Will be provided under separate cover.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SG/

INFORMATION DISCLOSURE CITATION IN AN APPLICATION	ATTY. DOCKET NO. **066783-0145**	SERIAL NO. **10/782,375**
	APPLICANT **Pulst et al.**	
(PTO-1449)	FILING DATE **February 18, 2004**	GROUP **1645**

	12.	DIANTONIO et al., "The effect on synaptic physiology of synaptotagmin mutations in Drosophila," Neuron. 12:909-920 (1993).	
	13.	DIANTONIO et al., "Synaptic transmission persists in synaptotagmin mutants of Drosophila," Cell 73:1281-1290 (1993).	
	14.	ELFERINK et al., "A role for synaptotagmin (p65) in regulated exocytosis," Cell 72:153-159 (1993).	
	15.	ENGELENDER et al., "Synphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusions," Nat. Genet. 22:110-114 (1999).	
	16.	FERNANDEZ-CHACON et al., "Synaptotagmin I functions as a calcium regulator of release probability," Nature 410:41-49 (2001).	
	17.	FINNEY et al., "The cellular protein level of parkin is regulated by its ubiquitin-like domain," J. Biol. Chem. 278:16054-16058 (2003).	
	18.	FUKUDA and MIKOSHIBA, "Characterization of KIAA1427 protein as an atypical synaptotagmin (Syt XIII)," Biochem. J. 354:249-257 (2001).	
	19.	FUKUDA et al., "A unique spacer domain of synaptotagmin IV is essential for Golgi localization," J. Neurochem. 77:730-740 (2001).	
	20.	FUKUDA et al., "Nerve growth factor-dependent sorting of synaptotagmin IV protein to mature dense-core vesicles that undergo calcium-dependent exocytosis in PC12 cells," J. Biol. Chem. 278:3220-3226 (2003).	
	21.	GEPPERT et al., "Synaptotagmin I: a major Ca2+ sensor for transmitter release at a central synapse," Cell 79(4):717-727 (1994).	
	22.	GERONA et al., "The C terminus of SNAP25 is essential for Ca^{2+}-dependent binding of synaptotagmin to SNARE complexes," J. Biol. Chem. 275:6328-6336 (2000).	
	23.	HAYASHI et al., "An autopsy case of autosomal-recessive juvenile parkinsonism with a homozygous exon 4 deletion in the parkin gene," Mov. Disord. 15:884-888 (2000).	
	24.	HUYNH et al., "Parkin is associated with actin filaments in neuronal and nonneuronal cells," Ann. Neurol. 48:737-744 (2000).	
	25.	HUYNH et al., "Parkin colocalizes with actin filaments and synaptic vesicles, and interacts with synaptotagmin XI," Abstr. Soc. Neurosci. 27:607, abstract 233.1, (2001).	
	26.	HUYNH et al., "Interaction of Parkin with vesicle-associated proteins," Neurology 58 (suppl. 3); A410 abstract S53.007 (2002).	
	27.	HUYNH et al., "The autosomal recessive juvenile Parkinson disease gene product, parkin, interacts with and ubiquitinates synaptotagmin XI," Hum. Mol. Genet. 12(20):2587-2597 (2003).	
	28.	IBATA et al., "Synaptotagmin IV is present at the golgi and distal parts of neuritis," J. Neurochem. 74:518-526 (2000).	
	29.	IMAI et al., "An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin," Cell 105:891-902 (2001).	

EXAMINER	DATE CONSIDERED
/Stephen Gucker/	06/21/2010

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
** This reference not attached. Will be provided under separate cover.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SG/

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)	ATTY. DOCKET NO. 066783-0145	SERIAL NO. 10/782,375
	APPLICANT Pulst et al.	
	FILING DATE February 18, 2004	GROUP 1645

	30.	IMAI et al., "CHIP is associated with Parkin, a gene responsible for familial Parkinson's disease, and enhances its ubiquitin ligase activity," Mol. Cell. 10:55-67 (2002).	
	31.	IMAI et al., "Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity," J. Biol. Chem. 275:35661-35664 (2000).	
	33.	ISHIKAWA and TAKAHASHI, "Clinical and neuropathological aspects of autosomal recessive juvenile parkinsonism," J. Neurol. 245(Suppl 3): p.4 – p.9 (1998).	
	33.	ISHIKAWA and TSUJI, "Clinical analysis of 17 patients in 12 Japanese families with autosomal-recessive type juvenile parkinsonism," Neurology 47:160-166 (1996).	
	38.	JOAZEIRO and WEISSMAN, "RING finger proteins: mediators of ubiquitin ligase activity," Cell 102:549-552 (2000).	
	33.	JORGENSEN et al., "Defective recycling of synaptic vesicles in synaptotagmin mutants of Caenorhabditis elegans," Nature 378:196-199 (1995).	
	36.	KITADA et al., "Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism," Nature 392:605-608 (1998).	
	31.	LE et al., "Mutations in NR4A2 associated with familial Parkinson disease," Nat. Genet. 33:85-89 (2003).	
	38.	LEVEQUE et al., "Calcium-dependent dissociation of synaptotagmin from synaptic SNARE complexes," J. Neurochem. 74:367-374 (2000).	
	39.	LI et al., "Ca^{2+}-dependent and -independent activities of neural and non-neural synaptotagmins," Nature 375:594-599 (1995).	
	40.	MATSUMINE, "A loss-of-function mechanism of nigral neuron death without Lewy body formation: autosomal recessive juvenile parkinsonism (AR-JP)," J. Neurol. 245(Suppl 3):10-14 (1998).	
	41.	MORI et al., "Pathologic and biochemical studies of juvenile parkinsonism linked to chromosome 6q," Neurology 51:890-892 (1998).	
	42.	MURPHEY and GODENSCHWEGE, "New roles for ubiquitin in the assembly and function of neuronal circuits," Neuron 36:5-8 (2002).	
	43.	NAOI et al., "Cell death of dopamine neurons in aging and Parkinson's disease," Mech. Ageing Dev. 111:175-188 (1999).	
	41.	POLYMEROPOULOS et al., "Mutation in the alpha-synuclein gene identified in families with Parkinson's disease," Science 276:2045-2047 (1997).	
	45.	REIST et al., "Morphologically docked synaptic vesicles are reduced in synaptotagmin mutants of Drosophila," J. Neurosci. 18:7662-7673 (1998).	
	46.	REN et al., "Parkin binds to alpha/beta tubulin and increases their ubiquitination and degradation," J. Neurosci. 23:3316-3324 (2003).	
	47.	RIBEIRO et al., "Synphilin-1 is developmentally localized to synaptic terminals, and its association with synaptic vesicles is modulated by alpha-synuclein," J. Biol. Chem. 277:23927-23933 (2002).	

EXAMINER	DATE CONSIDERED
/Stephen Gucker/	06/21/2010

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
** This reference not attached. Will be provided under separate cover.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SG/

INFORMATION DISCLOSURE CITATION IN AN APPLICATION	ATTY. DOCKET NO. 066783-0145	SERIAL NO. 10/782,375
	APPLICANT Pulst et al.	
(PTO-1449)	FILING DATE February 18, 2004	GROUP 1645

	48.	SCHIAVO et al., "Binding of the synaptic vesicle v-SNARE, synaptotagmin, to the plasma membrane t-SNARE, SNAP-25, can explain docked vesicles at neurotoxin-treated synapses," Proc. Natl. Acad. Sci. USA 94:997-1001 (1997).	
	49.	SCHLOSSMACHER et al., "Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies," Am. J. Pathol. 160:1655-1667 (2002).	
	50.	SCOLES et al., "Neurofibromatosis 2 tumour suppressor schwannomin interacts with betaII-spectrin," Nat. Genet. 18:354-359 (1998).	
	51.	SHIBATA et al., "A novel protein with RNA-binding motifs interacts with ataxin-2," Hum. Mol. Genet. 9:1303-1313 (2000).	
	52.	SHIMURA et al., "Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase," Nat. Genet. 25:302-305 (2000).	
	** 53.	SHIMURA et al., "Immunohistochemical and subcellular localization of Parkin protein: absence of protein in autosomal recessive juvenile parkinsonism patients," Ann. Neurol. 45:668-672 (1999).	
	54.	SHIMURA et al., "Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease," Science 293(5528):263-269 (2001).	
	55.	STAROPOLI et al., "Parkin is a component of an SCF-like ubiquitin ligase complex and protects postmitotic neurons from kainate excitotoxicity," Neuron 37:735-749 (2003).	
	56.	SUDHOF, "Synaptotagmins: why so many?," J. Biol. Chem. 277(10):7629-7632 (2001).	
	57.	TSAI et al., "Parkin facilitates the elimination of expanded polyglutamine proteins and leads to preservation of proteasome function," J. Biol. Chem. 278:22044-22055 (2003).	
	** 58.	VAN DE WARRENBURG et al., "Clinical and pathologic abnormalities in a family with parkinsonism and parkin gene mutations," Neurology 56:555-557 (2001).	
	59.	VOETS et al., "Intracellular calcium dependence of large dense-core vesicle exocytosis in the absence of synaptotagmin I," Proc. Natl. Acad. Sci. USA 98:11680-11685 (2001).	
	60.	VON POSER et al., "The evolutionary pressure to inactivate. A subclass of synaptotagmins with an amino acid substitution that abolishes Ca^{2+} binding," J. Biol. Chem. 272:14314-14319 (1997).	
	61.	WAKABAYASHI et al., "Immunocytochemical localization of synphilin-1, an alpha-synuclein-associated protein, in neurodegenerative disorders," Acta Neuropathol 103(3):209-214 (2002)	
	** 62.	WAKABAYASHI et al., "Synphilin-1 is present in Lewy bodies in Parkinson's disease," Ann. Neurol. 47:521-523 (2000).	
	63.	WANG et al., "Synaptotagmin modulation of fusion pore kinetics in regulated exocytosis of dense-core vesicles," Science 294:1111-1115 (2001).	
	64.	WINTERMEYER et al., "Mutation analysis and association studies of the UCHL1 gene in German Parkinson's disease patients," Neuroreport 11:2079-2082 (2000).	

EXAMINER	DATE CONSIDERED
/Stephen Gucker/	06/21/2010

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
** This reference not attached. Will be provided under separate cover.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SG/

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)	ATTY. DOCKET NO. 066783-0145	SERIAL NO. 10/782,375
	APPLICANT Pulst et al.	
	FILING DATE February 18, 2004	GROUP 1645

	65.	YAMADA et al., "Relative sparing in Parkinson's disease of substantia nigra dopamine neurons containing calbindin-$_{D28K}$," Brain Res. 526:303-307 (1990).	
	66.	ZHANG et al., "Parkin functions as an E2-dependent ubiquitin- protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1," Proc. Natl. Acad. Sci. USA 97:13354-13359 (2000).	
	67.	ZHANG et al., "Synaptotagmin I is a high affinity receptor for clathrin AP-2: implications for membrane recycling," Cell 78:751-760 (1994).	
	68.	~~Database EMBL accession no. BI041947~~	
	69.	~~Database EMBL accession no. BG704658~~	
	70.	~~GenBank accession number AI143220~~	
	71.	~~GenBank accession number AL135049~~	
	72.	~~GenBank accession number AW374529~~	
	73.	~~GenBank accession number BG039205~~	
	74.	~~GenBank accession number BG058917~~	
	75.	~~GenBank accession number BE899012~~	
	76.	~~GenBank accession number BE909317~~	
	77.	~~GenBank accession number BF666086~~	
	78.	~~GenBank accession number BE837913~~	
	79.	~~GenBank accession number BG113587~~	
	80.	~~GenBank accession number BG698684~~	
	81.	~~GenBank accession number BG745175~~	
	82.	~~GenBank accession number BG745945~~	
	83.	~~GenBank accession number BG765308~~	
	84.	~~GenBank accession number BI041947~~	
	85.	~~GenBank accession number BM910986~~	
	86.	~~GenBank accession number BM975158~~	
	87.	~~GenBank accession number BU542453~~	
	88.	~~GenBank accession number BU687172~~	
	89.	~~GenBank accession number CD614570~~	
	90.	~~GenBank accession number CD614574~~	
	91.	~~GenBank accession number CD614578~~	
	92.	~~GenBank accession number CD614588~~	
	93.	~~GenBank accession number CD614590~~	
	94.	~~GenBank accession number CD614592~~	

EXAMINER	DATE CONSIDERED
/Stephen Gucker/	06/21/2010

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
** This reference not attached. Will be provided under separate cover.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SG/

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (RTO-1449)	ATTY. DOCKET NO. 066783-0145	SERIAL NO. 10/782,375
	APPLICANT Pulst et al.	
	FILING DATE February 18, 2004	GROUP 1645

	95.	GenBank accession number CD614594	
	96.	GenBank accession number CD614596	
	97.	GenBank accession number CD614598	

No dates.

EXAMINER	DATE CONSIDERED
/Stephen Gucker/	06/21/2010

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
** This reference not attached. Will be provided under separate cover.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SG/